Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

CJC-1295 no DAC 5mg

$37.00

CJC1295 without DAC (Drug Affinity Complex), also known as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It is a modified version of Sermorelin, designed to stimulate the pituitary gland to naturally increase growth hormone (GH) production. Unlike the DAC-modified version, CJC1295 no DAC has a relatively short half-life, typically around 30 minutes to an hour, which results in a pulsatile release of growth hormone that more closely mimics the body's natural GH secretion patterns.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₁₅₂H₂₅₂N₄₄O₄₂
CAS Number 863288‑34‑0
Molar Mass 3367.94 g/mol
Amino Acid Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
PubChem CID 91976842
Primary Research Area GHRH Analog
Growth Hormone Secretagogue
Stimulate Endogenous GH/IGF-1
Muscle Growth
Fat Metabolism
Cellular Repair
Recovery Enhancement
Anti-aging Effects
Growth Hormone Deficiency
Lipodystrophy
Research Summary Description
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.

Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
What is CJC1295 without DAC? Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.

Citation: Bocsci. (n.d.). What is CJC1295 without DAC?
CJC-1295 for beginners: How it works, benefits, dosage, and stacks Summary: This article explains that CJC1295 functions by mimicking the body's natural GHRH, stimulating the pituitary gland to release more GH in a pulsatile manner. This mechanism differs from direct exogenous GH administration, which introduces external hormone.

Citation: Swolverine. (n.d.). CJC-1295 for Beginners: How it Works, Benefits, Dosage, and Stacks.
CJC-1295 No DAC vs. CJC-1295 DAC: Key differences, benefits, and best uses Summary: This article details that CJC-1295 No DAC produces a pulsatile release of growth hormone that more closely mimics the body's natural GH secretion patterns, often favored for anti-aging, skin rejuvenation, and recovery applications to maintain receptor sensitivity.

Citation: Swolverine. (n.d.). CJC-1295 No DAC vs. CJC-1295 DAC: Key Differences, Benefits, and Best Uses.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.

Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.

Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
CJC-1295 Peptide therapy: Anti-aging, hormone & functional medicine Summary: This source describes CJC-1295 (including the no DAC version, often referred to as ""Modified GRF 1-29"") as a GHRH analog that stimulates the pituitary gland to release more growth hormone, subsequently increasing IGF-1. It highlights that the ""no DAC"" version is often preferred for its short half-life, which allows for a more natural, pulsatile release of GH. Reported benefits include increased muscle mass and strength, decreased body fat, enhanced recovery, deeper sleep, improved cognitive function, and anti-aging effects on skin and hair. It also mentions common combination use with Ipamorelin for synergistic effects.

Citation:
Re-New Institute. (n.d.). CJC 1295. Retrieved from https://www.re-newinstitute.com/content/cjc-1295

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.

Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.

What is CJC1295 without DAC?

Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.

Citation: Bocsci. (n.d.). What is CJC1295 without DAC?

CJC-1295 for beginners: How it works, benefits, dosage, and stacks

Summary: This article explains that CJC1295 functions by mimicking the body's natural GHRH, stimulating the pituitary gland to release more GH in a pulsatile manner. This mechanism differs from direct exogenous GH administration, which introduces external hormone.

Citation: Swolverine. (n.d.). CJC-1295 for Beginners: How it Works, Benefits, Dosage, and Stacks.

CJC-1295 No DAC vs. CJC-1295 DAC: Key differences, benefits, and best uses

Summary: This article details that CJC-1295 No DAC produces a pulsatile release of growth hormone that more closely mimics the body's natural GH secretion patterns, often favored for anti-aging, skin rejuvenation, and recovery applications to maintain receptor sensitivity.

Citation: Swolverine. (n.d.). CJC-1295 No DAC vs. CJC-1295 DAC: Key Differences, Benefits, and Best Uses.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.

Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.

Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

CJC-1295 Peptide therapy: Anti-aging, hormone & functional medicine

Summary: This source describes CJC-1295 (including the no DAC version, often referred to as ""Modified GRF 1-29"") as a GHRH analog that stimulates the pituitary gland to release more growth hormone, subsequently increasing IGF-1. It highlights that the ""no DAC"" version is often preferred for its short half-life, which allows for a more natural, pulsatile release of GH. Reported benefits include increased muscle mass and strength, decreased body fat, enhanced recovery, deeper sleep, improved cognitive function, and anti-aging effects on skin and hair. It also mentions common combination use with Ipamorelin for synergistic effects.

Citation:
Re-New Institute. (n.d.). CJC 1295. Retrieved from https://www.re-newinstitute.com/content/cjc-1295

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping